ClinicalTrials.gg
CompletedNCT03376503Updated Dec 19, 2017

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

A Phase 1 interventional study of Pegfilgrastim in Breast Cancer, sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company. Completed at 1 site in Vietnam. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-12-19.

Sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2016, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies testing pegfilgrastim in Breast Neoplasms — 2 open to participants now, 4 under way, 1 of them phase 3. pegfilgrastim · Breast Neoplasms.

Enrollment
29th of 30
24 · median 124
Started
2016
with 2 others
Phase 1
Only one
of the 33
Registered
27th of 33
by date
Lead sponsor
2 of 33
Nanogen Pharmaceutical Biotechnology Joint Stock Company

Among the 33 studies testing pegfilgrastim in Breast Neoplasms, this one is the 29th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2016, is the only one in phase 1, and was the 27th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 33 studies testing pegfilgrastim in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing pegfilgrastim in Breast Neoplasms, or all of them as a file.
02

Study summary

Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be enrolled in this study. Eligible patients receive single SC injection of pegcyte or neulastim 24 hours after administration of chemotherapy (Doxorubicin and Cyclophosphamide) in the first cycle (14 days each cycle). Blood samples are collected to determine the serum concentration of investigational drugs at specific time points in the first cycle. Absolute neutrophil count, CD34+ count, Cmax (maximum serum concentration), AUC0-t (area under the curve of the plasma concentration time) and Tmax (time required to reach Cmax) will be calculated from the serum concentration profile

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged between 18 - 65 years.
  • Patients with histological confirmed primary invasive breast cancer; stage I, II or III.
  • Patients had no prior chemotherapy treatments.
  • Patients scheduled to undergo myelosuppressive Doxorubicin and Cyclophosphamide chemotherapy for 04 cycles, and Paclitaxel chemotherapy for the next 04 cycles; patients were available for 14 days of each cycle for the first 03 chemotherapy cycles.
  • Patients with baseline ≥ 1.5 x 109/L, ≥ 100 x 109/L, HgB ≥ 9 g/dL, WBC ≥ 3,000/mL and albumin ≥ 3.0 g/dL.
  • Performance status as per (Eastern Cooperative Oncology Group) score 0, 1 or 2.
  • Willing to give written and signed

Exclusion criteria

Exclusion Criteria:

  • Patients with prior exposure of G-CSF or GM-CSF or its pegylated products in clinical development less than 6 months prior to randomization.
  • Myelotoxic concomitant treatment such as chloramphenicol, methotrexate, immunomodulating agents, interferons during 10 days before randomization.
  • Received systemic antibiotic treatment within 72 hours of chemotherapy.
  • Chronic use of , prior bone marrow or stem cell transplant.
  • Patients who had an immediate/ concurrent exposure to radiotherapy or surgery (within 4 weeks).
  • Severe medical disease: cardiovascular, hepatic, renal, pulmonary...
  • Known cases of hematological disease (sickle cell anemia, AML...)
  • History of positive, active hepatitis.
  • Pregnant and lactating women or patients planning to become pregnant.
  • Known allergic reactions to study medications.
  • Positive to anti-pegfilgrastim antibody test.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Pegcyte (Nanogen pegfilgrastim)

    pegcyte 6 mg in the first cycle

    Drug: Pegfilgrastim

  • Active comparator
    Neulastim (Roche pegfilgrastim)

    Neulastim 6 mg in the first cycle

    Drug: Pegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve from time 0 to the last time point (AUC0-t) for serum Pegfilgrastim (PEG-GCSF)

    (AUC0-t)

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

Secondary outcomes

  1. Apparent clearance (CL) for serum Pegfilgrastim

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  2. Maximum concentration (Cmax) for serum Pegfilgrastim

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  3. Half-life (T½) for serum Pegfilgrastim (PEG-GCSF)

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  4. Area under the serum concentration-time curve (AUC0-inf) of Pegfilgrastim

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  5. Time to maximum concentration (Tmax) for serum Pegfilgrastim

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  6. Terminal elimination rate constant (λz) for serum Pegfilgrastim

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  7. Maximum change in CD34+ count

    Time frame: day 2 (0h), day 5 (72h), day 7 (120h), and day 8 (144h) of the first cycle.

  8. Area under the curve above baseline of ANC [ANC_AUC(0-tlast)]

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  9. Time of maximum change from baseline for ANC in days (ANC_Tmax)

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  10. Maximum change from baseline in absolute neutrophil count from time 0 to the last time point ANC AUC0-t

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  11. Maximum change from baseline in absolute neutrophil count (ANC); ANC_Cmax

    Time frame: day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle

  12. Incidence of adverse events

    Including changes in vitals and laboratory investigations

    Time frame: cycle 1 from day 2 to day 14

07

Study locations

1 site
  • Vietnam National Cancer Institute (Hospital K)
    Hanoi, Vietnam
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Oct 2017, 16 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 16 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2017
First posted
Dec 18, 2017
StartActual
May 25, 2016
Primary completionActual
Oct 9, 2017
CompletionActual
Nov 6, 2017
Last update
Dec 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03376503
Lead sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
May 25, 2016
Primary completion
Oct 9, 2017
Completion
Nov 6, 2017
Last update
Dec 19, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion